Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Torsdag 24 April | 11:58:14 Europe / Stockholm

Svenska | English

BioStock

Lipum AB: BioStock: Lipum looks ahead to phase II with backing from Flerie

2025-04-22 10:01:32

Lipum has finalised the clinical study report for its phase I trial of the drug candidate SOL-116, officially concluding the study. The company's largest shareholder, Flerie, played a key role in supporting the execution of the trial. To gain further insight, we spoke with Karl Elmqvist, Investment Manager at Flerie, and Ola Sandborgh, CEO of Lipum.
- The phase I results give us strong confidence as SOL-116 progresses to the next stage of development, says Karl Elmqvist.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/04/lipum-looks-ahead-to-phase-ii-with-backing-from-flerie/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden